Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with voiding difficulty: a randomized clinical trial

Hajebrahimi, Sakineh; AsrBadr, Yadollah Ahmadi; Azaripour, Arash; Sadeghi‐Bazargani, Homayoun

doi:10.2147/ijgm.s16063

Cited by 20 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…De mate van obstructie, gemeten met de PdetQmax ten opzicht van de Qmax, had geen invloed op de effectiviteit van de α1-adrenerge receptorantagonist [10]. In de vijf RCT's [15][16][17][18][19] werden vergelijkbare verbeteringen beschreven, maar in vier van de vijf van RCT's met een placebogroep verbeterden niet alle uitkomstmaten significant [16][17][18][19]. In de studie van Lepor en Theune verbeterde de AUASS bijvoorbeeld niet significant [18].…”

Section: Resultatenunclassified

Een α‑adrenerge receptorantagonist als behandeling van blaasontledigingsklachten bij vrouwen: Feit of fictie?

2018

View full text Add to dashboard Cite

SamenvattingDe behandeling van blaasontledigingsklachten bij vrouwen bestaat momenteel uit bekkenbodemfysiotherapie en intermitterende zelfkatheterisatie. Dit artikel betreft de effectiviteit van een α1-adrenerge receptorantagonist bij deze vrouwen. Hiertoe hebben wij gekeken naar de recente literatuur en de uitkomst van 11 klinische studies. De resultaten van de verschillende studies laten zien dat bij de interventiegroep de International Prostate Symptoms Score (IPSS), evenals de Qmax en de, PdetQmax significant verbeteren en het residu significant vermindert. In de onderzoeken met een placebogroep verbeterden de urodynamische parameters echter niet significant. Mede gezien de in-vitro-effectiviteit, het minimale bijwerkingenprofiel en de huidige bewijskracht, valt bij vrouwen met blaasontledigingsklachten behandeling met een α1-adrenerge receptorantagonist te overwegen. De bewijskracht hiervoor is echter matig, mede door de uiteenlopende uitkomstmaten in de verschillende studies en het ontbreken van voldoende gerandomiseerde studies. Trefwoorden blaasontledigingsklachten · vrouwen · α1-adrenerge receptorantagonistAn α-adrenerg receptor antagonist as treatment of bladder outflow obstruction in women: Fact or fiction? Abstract At present, the treatment of bladder outflow obstruction (BOO) in women is limited to pelvic floor physiotherapy or intermittent self-catheterization. The goal of this article is to explore the effectivity of an α1-adrenergic receptor antagonist for these women. For this, we looked at the literature and included eleven clinical trials. Comparing results shows consistent significant improvement in IPSS, the Qmax, PdetQmax and residual volume after micturition in the intervention group. However, there are no significant differences in urodynamic outcome parameters between the intervention and placebo group. Based on the in vitro results, the minimal side effects and the suggested clinical effectiveness, an α1-adrenergic receptor antagonist is an option to consider in women with BOO. However, the current quality of evidence is moderate, because of the diversity in outcome measures and the absence of multiple randomized trials.Keywords bladder outflow obstruction · female · α1-adrenergic receptor antagonist drs. Marlous L. E. Vermeulen

show abstract

Section: Resultatenunclassified

Een α‑adrenerge receptorantagonist als behandeling van blaasontledigingsklachten bij vrouwen: Feit of fictie?

2018

View full text Add to dashboard Cite

show abstract

“…Thus, many clinicians have prescribed similar treatments to women with LUTS based on the assumption that α1-blockers will similarly affect the female bladder neck. Some open-label prospective trials [16-19,21,23,24,27] and RCTs [5,6,20,22,25,26] have examined the effect of α1-blockers on female voiding dysfunction. However, the outcomes of these studies have not been consistent.…”

Section: Discussionmentioning

confidence: 99%

Alpha-1 Adrenergic Receptor Blockers for the Treatment of Lower Urinary Tract Symptoms in Women: A Systematic Review and Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Purpose To assess the effectiveness of alpha-1 adrenergic receptor blockers (α1-blockers) in the treatment of female lower urinary tract symptoms (LUTS). Methods A literature search was conducted using the PubMed/MEDLINE, Embase, and Cochrane Library databases. Fourteen studies with 1,319 patients were ultimately included. The study comprised 2 analyses: a comparison of urinary symptom scores, maximal flow rate (Qmax), and postvoid residual (PVR) urine volume before and after α1-blocker administration in 8 prospective, open-label studies and 5 randomized clinical trials (RCTs); and an evaluation of the same variables in α1-blocker and placebo groups in 4 RCTs. Results The first meta-analysis showed that, following treatment, patients exhibited statistically significant symptom relief (mean difference [MD], -5.85; 95% confidence interval [CI], -7.71 to -3.99; P<0.00001), increased Qmax (MD, 3.67 mL/sec; 95% CI, 2.76–4.59 mL/sec; P<0.00001), and decreased PVR volume (MD, -28.46 mL; 95% CI, -34.99 to -21.93 mL; P<0.00001). In the second meta-analysis, α1-blockers demonstrated significant symptom relief relative to placebo (MD, -1.60; 95% CI, -2.68 to -0.51; P=0.004). However, no significant differences were observed in Qmax (MD, 0.05 mL/sec; 95% CI, -0.74 to 0.83 mL/sec, P=0.91) and PVR (MD, -8.10 mL; 95% CI, -32.32 to 16.12 mL, P=0.51) between the α1-blocker and placebo groups. Conclusions These analyses suggest that α1-blockers are effective in the treatment of female LUTS patients. However, the effect of α1-blockers on female LUTS should be assessed according to the underlying cause, and the role of α1-blockers in combination therapy with other drugs should also be investigated.

show abstract

“…These interventions include conservative treatment (as an alternative modalities to drugs in patients with motivation, or ineffectiveness of drugs or the present of drug side effects in long time users such as pelvic floor muscle training, biofeedback, bladder training, however, the evidences about its effect are poor), behavioral modification, bladder reflex triggering and bladder expression; medical management (anticholinergic and l ‐dopa); clean intermittent (in/out) catheterization (CIC) and the indwelling catheters; electrical stimulation; sacral nerve roots stimulation; dorsal penile and clitoral nerves electrical stimulation; tibial nerve stimulation; neuromodulation; magnetic stimulation; deep brain stimulation (DBS); intravesical application of several neurotoxic agents (including capsaicin, resiniferatoxin, and botulinum toxin [BTX]); sacral roots stimulation by dorsal rhizotomy; antiparkinsonian therapy; surgery (TURP); and augmentation cystoplasty …”

Section: Introductionmentioning

confidence: 99%

Management of neurogenic bladder in patients with Parkinson's disease: A systematic review

Hajebrahimi

Chapple

Pashazadeh

et al. 2018

Neurourology and Urodynamics

Self Cite

View full text Add to dashboard Cite

Aims:To assess the different treatment methods in management of neurogenic bladder (NGB) in patients with Parkinson's disease (PD). Methods: A systematic search was performed in Cochrane library, EMBASE, Proquest, Clinicaltrial.gov, WHO, Google Scholar, MEDLINE via PubMed, Ovid, ongoing trials registers, and conference proceedings in November 11, 2017. All randomized controlled trials (RCTs) or quasi-RCTs comparing any treatment method for management of NGB in patients with PD were included. The titles and abstracts of all identified studies were evaluated independently by two investigators. Once all of the potential related articles were retrieved, each author separately evaluated the full text of each article and the quality of the methodology of the selected studies using the Cochrane appraisal risk of bias checklist and then the data about the patient's outcomes was extracted. We registered the title in Joanna Briggs Institute (JBI) that is available in http://joannabriggs.org/research/registered_titles.aspx. Results: We included 41 RCTs or quasi-RCTs or three observational study with a total of 1063 patients that evaluated pharmacological, neurosurgical, botulinum toxin, electrical neuromodulation, and behavioral therapy effects on NGB. Among the included studies only solifenacin succinate double-blind, randomized, placebocontrolled study was assessed as low risk of bias, and treatment led to an improvement in urinary incontinence. Conclusions: Although several interventions are available for treatment NGB in patients with PD, at present there is little or no evidence that treatment improves patient outcomes in this population. Additional large, well designed, randomized studies with improved methodology and reporting focused on patient-centered outcomes are needed.

show abstract

Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with voiding difficulty: a randomized clinical trial

Cited by 20 publications

References 13 publications

Een α‑adrenerge receptorantagonist als behandeling van blaasontledigingsklachten bij vrouwen: Feit of fictie?

Een α‑adrenerge receptorantagonist als behandeling van blaasontledigingsklachten bij vrouwen: Feit of fictie?

Alpha-1 Adrenergic Receptor Blockers for the Treatment of Lower Urinary Tract Symptoms in Women: A Systematic Review and Meta-Analysis

Management of neurogenic bladder in patients with Parkinson's disease: A systematic review

Contact Info

Product

Resources

About